Cargando…

Patients’ preferences for headache acute and preventive treatment

BACKGROUND: We aimed to explore patients’ preferences for headache treatments with a self-administered questionnaire including the Q-No questionnaire for nocebo. METHODS: Questionnaires from 514 outpatients naïve to neurostimulation and monoclonal antibodies were collected. RESULTS: Patients assesse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mitsikostas, Dimos D., Belesioti, Ioanna, Arvaniti, Chryssa, Mitropoulou, Euthymia, Deligianni, Christina, Kasioti, Elina, Constantinidis, Theodoros, Dermitzakis, Manolis, Vikelis, Michail
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Milan 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630539/ https://www.ncbi.nlm.nih.gov/pubmed/28986900 http://dx.doi.org/10.1186/s10194-017-0813-3

Ejemplares similares

Consensus of the Hellenic Headache Society on the diagnosis and treatment of migraine
por: Kouremenos, Evangelos, et al.
Publicado: (2019)

Onabotulinumtoxin-A treatment in Greek patients with chronic migraine
por: Vikelis, Michail, et al.
Publicado: (2016)

Sumatriptan transdermal iontophoretic patch (NP101-Zelrix™): review of pharmacology, clinical efficacy, and safety in the acute treatment of migraine
por: Vikelis, Michail, et al.
Publicado: (2012)

Treatment and outcome in medication overuse headache patients
por: Mitsikostas, D, et al.
Publicado: (2013)

Treating primary headaches – management of migraine
por: Mitsikostas, Dimos D
Publicado: (2013)

Are indirect comparisons for treatments in migraine necessitas? Many inevitable challenges to overcome
por: Deligianni, Christina, et al.
Publicado: (2023)

EHMTI-0335. Depression and anxiety symptoms in patients suffering from new daily persistent headache. A prospective, controlled study
por: Deligianni, C, et al.
Publicado: (2014)

Refractory burning mouth syndrome: clinical and paraclinical evaluation, comorbidities, treatment and outcome
por: Mitsikostas, Dimos D., et al.
Publicado: (2017)

Headache attributed to unruptured saccular aneurysm, mimicking hemicrania continua
por: Vikelis, M., et al.
Publicado: (2005)

Guidelines for the organization of headache education in Europe: the headache school II
por: Jensen, Rigmor, et al.
Publicado: (2010)

Monoclonal Antibodies Targeting CGRP: From Clinical Studies to Real-World Evidence—What Do We Know So Far?
por: Mavridis, Theodoros, et al.
Publicado: (2021)

Neck pain in episodic migraine: premonitory symptom or part of the attack?
por: Lampl, Christian, et al.
Publicado: (2015)

Cluster headache: a quasi-rare disorder needing a reappraisal
por: Martelletti, Paolo, et al.
Publicado: (2015)

Refractory Headache: One Term does Not cover All – A Statement of the European Headache Federation
por: Lampl, Christian, et al.
Publicado: (2014)

Nocebo in Biosimilars and Generics in Neurology: A Systematic Review
por: Spanou, Ioanna, et al.
Publicado: (2019)

Cluster headache in Greece: an observational clinical and demographic study of 302 patients
por: Vikelis, Michail, et al.
Publicado: (2016)

Evidence That HFE H63D Variant Is a Potential Disease Modifier in Cluster Headache
por: Papasavva, Maria, et al.
Publicado: (2021)

Headache Attributed to Reversible Cerebral Vasoconstriction Syndrome (RCVS)
por: Tentolouris-Piperas, Vasileios, et al.
Publicado: (2023)

Gleaning after the European Headache Federation consensus statement on refractory chronic migraine
por: Martelletti, Paolo, et al.
Publicado: (2014)

European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
por: Sacco, Simona, et al.
Publicado: (2019)

Assessing the Significance of the Circadian Time of Administration on the Effectiveness and Tolerability of OnabotulinumtoxinA for Chronic Migraine Prophylaxis
por: Dermitzakis, Emmanouil V., et al.
Publicado: (2022)

Prospective Comparison of Longer Needle Lengths to Assess the Risk of OnabotulinumtoxinA-Associated Neck Pain in Patients with Chronic Migraine
por: Dermitzakis, Emmanouil V., et al.
Publicado: (2022)

OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine
por: Argyriou, Andreas A., et al.
Publicado: (2022)

Correction to: European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
por: Sacco, Simona, et al.
Publicado: (2019)

Structured headache services as the solution to the ill-health burden of headache. 2. Modelling effectiveness and cost-effectiveness of implementation in Europe: methodology
por: Tinelli, Michela, et al.
Publicado: (2021)

European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update
por: Sacco, Simona, et al.
Publicado: (2022)

Predictors of Response to Fremanezumab in Migraine Patients with at Least Three Previous Preventive Failures: Post Hoc Analysis of a Prospective, Multicenter, Real-World Greek Registry
por: Argyriou, Andreas A., et al.
Publicado: (2023)

The Role of Galcanezumab in Migraine Prevention: Existing Data and Future Directions
por: Gklinos, Panagiotis, et al.
Publicado: (2021)

New players in the preventive treatment of migraine
por: Mitsikostas, Dimos D., et al.
Publicado: (2015)

Structured headache services as the solution to the ill-health burden of headache. 3. Modelling effectiveness and cost-effectiveness of implementation in Europe: findings and conclusions
por: Tinelli, Michela, et al.
Publicado: (2021)

EHMTI-0331. Q-No: a questionnaire to predict nocebo in outpatients seeking neurological consultation
por: Deligianni, C, et al.
Publicado: (2014)

Variables affecting factors associated with primary headache
por: Alexoudi, Athanasia, et al.
Publicado: (2018)

Male and female sex hormones in primary headaches
por: Delaruelle, Zoë, et al.
Publicado: (2018)

Galcanezumab in migraine prevention: a systematic review and meta-analysis of randomized controlled trials
por: Gklinos, Panagiotis, et al.
Publicado: (2020)

Refractory chronic cluster headache: a consensus statement on clinical definition from the European Headache Federation
por: Mitsikostas, Dimos D, et al.
Publicado: (2014)

Results of a Web-Based Survey on 2105 Greek Migraine Patients—Second Part: Efficacy of Acute and Prophylactic Migraine Treatments and Corresponding Patients’ Reported Satisfaction
por: Dermitzakis, Emmanouil V., et al.
Publicado: (2022)

B-Cell Targeted Therapies in Patients with Multiple Sclerosis and Incidence of Headache: A Systematic Review and Meta-Analysis
por: Mavridis, Theodoros, et al.
Publicado: (2022)

Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation
por: Bendtsen, Lars, et al.
Publicado: (2018)

Framing education on headache disorders into the Global Burden of Disease Study 2010. The European Headache Federation stands ready
por: Martelletti, Paolo, et al.
Publicado: (2013)

Headaches in the emergency department –a survey of patients’ characteristics, facts and needs
por: Doretti, Alberto, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_p43l31r3kj6okgcm3o4n58j4h5